Aim-A crossover, randomised double blind study was undertaken in 30 healthy volunteers, in order to compare the tolerance of 2% carteolol with and without preservative in short term use. Methods-Complete ophthalmic examinations were performed before and 30, 60, and 180 minutes after instillation of one drop of the solution, and after 3 days of preservative treatment. After a 5 day washout, the same examinations were done with the second drug. Results-Results showed good general tolerance for both formulations. No significant diVerence in subjective tolerance, corneal aesthesiometry, punctuate keratitis, Schirmer's test, intraocular pressure (IOP) decrease (about 25% in the two groups at 3 hours, 10% after 3 days of treatment), resting cardiac frequency, or blood pressure was observed. However, break up time was significantly reduced from baseline by preserved carteolol both at 3 hours (10.40 (5.9) seconds to 6.15 (3.9) seconds, p=0.001) and after 3 days (7.72 (5.5) seconds, p=0.04). Preservative free carteolol did not significantly change the break up time (baseline 9.08 (5.7) seconds; 3 hours = 7.88 (5.5) seconds, not significant; day 3 = 8.35 (5.8), non-significant). Conclusions-These results confirm that carteolol is well tolerated, either with or without preservative. The preservative free group showed better stability of the tear film, without loss of eVect on IOP. This diVerence, although mild in the healthy young subjects in the present study could be much more relevant in those patients treated long term, older patients, and/or those suVering from ocular surface disorders. In such instances, preservative free drugs could be of potential benefit to protect the lacrimal fluid integrity and corneoconjunctival surface. (Br J Ophthalmol 1998;82:39-42) 
Long term use of antiglaucoma drugs has been associated with toxic as well as inflammatory changes of the ocular surface. Conjunctival biopsies taken at the time of glaucoma surgery have demonstrated a significant increase in immune cells and fibroblasts, possibly related to cumulative treatments with antiglaucoma drugs. 1 2 Impression cytology specimens from long term treated patients have shown significant metaplastic changes 3 and abnormal induction of inflammatory markers by epithelial cells in about 50% of eyes. 4 Clinically these inflammatory and fibrotic anomalies may result in pseudopemphigoid, 5 foreshortening of inferior fornix, 6 or significant reduction of success rate in glaucoma surgery. 7 8 However, little is known concerning the accurate mechanisms of such toxic side eVects in long term and/or multitreated glaucoma patients. Is the active drug responsible, as suggested by the significant toxicity demonstrated by adrenalin derivatives? Is it the preservative, benzalkonium chloride, which has shown toxicity on the ocular surface epithelia, 9 or the eventual additive a consequence of their association? Very few studies have been done in humans and they have indicated an improvement at the ocular surface level following removal of preservative from the solution of the glaucoma medication. [10] [11] [12] We thus undertook this prospective, crossover, double blind study in healthy volunteers, to compare, in short term use, the eVects of 2% carteolol, a topical blocker with intrinsic sympathomimetic activity, widely used in the treatment of primary open angle glaucoma, 13 with and without benzalkonium chloride.
Patients and methods

PATIENT SELECTION
This study was performed in healthy volunteers, in the Centre of Clinical Pharmacology of the University of Nice, France, after receiving the authorisation of the ethics committee (CCPPRB) of Marseilles, France. Selection criteria were: informed consent, age ranging from 18 to 40 years, normal ophthalmic examination, including best corrected visual acuity above 20/25, no subjective sensation such as itching, foreign body sensation or burning, normal slit lamp examination, break up time above or equal to 5 seconds, negative fluorescein staining, Schirmer's test superior or equal to 6 mm at 5 minutes, and IOP between 8 and 18 mm Hg. Subjects with history of ocular disease, cardiac or respiratory contraindication to blockers, topical or systemic medicines for less than 7 days before the experiment, except oral contraception, myopia more than 4 dioptres, history of ocular allergy, contact lens wearing, monophthalmos, or risk of pregnancy were not selected. Moreover, electrocardiogram, resting heart rate, and systemic pressure were recorded in the last 2 weeks before study. Subjects with any abnormality were not selected. At the end of the selection period, 30 healthy volunteers conformed to all these criteria and took part in the study.
STUDY DESIGN
Solutions of 2% carteolol were prepared with and without benzalkonium chloride (0.005%, as in the commercial solution: Cartéol, manufactured by Chauvin, Montpellier, France), in identical vials numbered in a randomised manner. One bottle was used for each instillation, so that six vials were used for each study period. Only one eye was tested and received the two formulations successively. Fifteen subjects received drugs into their right eye and the other 15 into the left eye. Drug and eye assignments were done with the help of a randomised computerised method. During the first study period, ophthalmic examinations were performed immediately before and 30, 60, and 180 minutes after the instillation of one drop of the tested solution. Subjects then instilled one drop twice a day for 2 days and one drop in the morning of the third day. New ophthalmic and general examinations were done 8 hours after the last instillation. After a 5 day washout period, the same experiment was done in the same eye, with the other solution.
CLINICAL EXAMINATIONS
Before the first instillation of carteolol solution, systemic pressure, heart rate, distant visual acuity, aesthesiometry, pupillary diameter, slit lamp scoring of conjunctival hyperaemia, oedema and epiphora, break up time, given by the mean of two successive measurements, fluorescein test, graded 0 to 4 according to the extent of staining, Schirmer's test at 5 minutes and applanation tonometry were recorded. In order to avoid a possible interaction with the preservative included in the anaesthetic used for applanation tonometry, we used a non-preserved anaesthetic (0.4% oxybuprocaine, Cebesine, Chauvin). The carteolol solution was administered 30 minutes after applanation tonometry to avoid any interference of the anaesthetic in evaluation of tolerance. After the first instillation, immediate tolerance was therefore evaluated by the subject on a visual analogue scale from 0 (not irritating) to 100 (extremely irritating), and subjective sensations of itching, burning, foreign body sensation, and photophobia were recorded at 10 minutes by a scoring system of intensity ranging from 0 to 3. If available, duration of sensation was recorded. All ophthalmic examinations were repeated at 30, 60, and 180 minutes, except pupil diameter and Schirmer's test. Systemic tension and heart pulse rate were recorded at 60 and 180 minutes. Following repeated administration, all examinations were performed 8 hours after the last instillation in each period. The second period was conducted under the same protocol with the other solution tested.
STATISTICAL ANALYSES
Comparability of subjects assigned to treatment sequence 1 (carteolol with benzalkonium followed by unpreserved carteolol) and sequence 2 (unpreserved carteolol followed by the preserved solution) was assessed for each criterion using the Mann-Whitney nonparametric test. No carryover eVect was detected and therefore data of both sequences were pooled. Analysis of variance was performed for each variable and time. In case of significant diVerence, Mann-Whitney U test or Wilcoxon test for paired variables were performed. p Values under or equal to 0.05 were considered significant.
Results
The 30 volunteers in this study were 18 females and 12 males, 19 to 40 years old. Their mean age was 26.7 (SD 5.2) years. At the beginning of the study, before the first instillation, the two groups were fully comparable, as eyes receiving benzalkonium or not did not differ significantly in any ophthalmic or systemic criterion tested. Very few side eVects were observed during the study. They were limited to three mild superficial punctate keratitis (two cases with benzalkonium and one case in the preservative free group), that were resolved in a few days without treatment, and did not call for the experiment to be stopped.
SINGLE INSTILLATION
Subjective tolerance at instillation quantified by a visual analogue scale from 0 to 100 mm showed a very good tolerance in both groups-3.66 (6.33) mm with carteolol with benzalkonium, v 2.83 (5.83) mm with preservative free carteolol (p=0.27, non-significant). No significant diVerence could be found between the two groups in grading of subjective symptoms, visual acuity, aesthesiometry, pupillary diameter, conjunctival oedema, epiphora, and fluorescein test scoring. None of these criteria changed significantly from baseline in any group.
Break up time, however, was significantly reduced compared with baseline by preserved carteolol at 3 hours (10.4 (5.9) seconds to 6.1 (3.9) seconds, p=0.001), whereas benzalkonium free carteolol did not change the break up time significantly (baseline 9.1 (5.7) seconds; 3 hours 7.9 (5.5) seconds, not significant). At this time point, the decrease of break up time from baseline was significantly higher in the benzalkonium group (−4.4 (6.3) seconds) than in the preservative free one (−1.1 (6.4) seconds, p=0.04).
IOP was similarly lowered in both groups, about −3 mm Hg. This was approximately a 25% reduction, without any diVerence between the two treatments (Table 1) . Blood pressure showed a very slight decrease after instillation of both formulations, less than 5 mm Hg for diastolic pressure and less than 10 mm Hg for systolic pressure, with no significant diVerence between the two groups. Resting pulse rate also decreased after instillation, with no significant diVerence between the two treatments ( Table 2) .
REPEATED INSTILLATIONS
After 3 days of treatment (six instillations), no diVerence could be found between the two treatments with regard to visual acuity, aesthesiometry, pupillary diameter, Schirmer's test, hyperaemia, oedema, epiphora, fluorescein test scores, or IOP (Table 3) . Again a trend towards better preservation of break up time was found in the group without benzalkonium, as it decreased from 9.1 (5.7) to 8.4 (5.8) seconds (not significant) v 10.4 (5.9) to 7.7 (5.5) seconds in the benzalkonium group (p=0.04). A slight IOP decrease was found in both groups 8 hours after the last instillation (about 10% from the baseline and similar with both treatments). A very slight decrease in blood pressure was found in both groups (mean decrease of 5% from the baseline, less than 6 mm Hg for systolic pressure, and 9%, less than 5 mm Hg, for diastolic), whereas heart frequency did not change significantly from the baseline in any group.
Discussion
Almost all antiglaucoma drugs are currently available in association with benzalkonium chloride, a quaternary cationic surfactant, used at concentrations ranging from 0.005% to 0.01%. Its ocular toxicity was documented as early as 1941, and was found relevant at concentrations as low as 0.004%. 9 Benzalkonium chloride through its surfactant eVects alters tear fluid stability and reduces break up time. At a concentration of 0.005%, benzalkonium chloride causes epithelial cell wrinkling and peeling with exposure of underlying cells. 14 At 0.01%, it may induce strong epithelial alterations, and at higher concentrations it causes strong damage to corneal stroma and endothelium.
Only a few studies have compared preservative free antiglaucoma drugs to preserved commercial preparations. In vitro, Williams et al 15 investigated benzalkonium chloride, and three pure and preserved blockers (timolol, betaxolol, and levobunolol), in tissue cultures of human Tenon's capsule fibroblasts, and demonstrated irreversible toxicity of preservative and preserved drugs. Preservative free timolol showed significantly less toxicity than the commercial solution with 0.01% benzalkonium, and levobunolol was the least toxic, probably as a result of a lower concentration of benzalkonium chloride in this preparation (0.004% benzalkonium). In experimental models, Young et al 16 showed, after glaucoma surgery, more myofibroblasts in the conjunctiva of rabbits treated for 4 months before surgery with pilocarpine, timolol, or artificial tears with benzalkonium chloride. An increase of fibrous tissue has also been observed in rabbits treated with preparations of metipranolol and pilocarpine, preserved with benzalkonium and cetrimonium chloride respectively, for 3 months, compared with non-preserved drugs. 17 In humans, a recent study of 20 patients by from timolol with benzalkonium to timolol without preservative could significantly increase tear turnover values, although break up time remained significantly lower both in benzalkonium and benzalkonium free timolol compared with normal control subjects, without a significant diVerence in the two groups. This may indicate that glaucoma drugs may impair the tear film, but that use of benzalkonium chloride entails additional side eVects. In other studies in glaucoma patients, removal of benzalkonium chloride from a timolol preparation restored the permeability and the metabolism of corneal epithelium 11 and improved break up time. 10 However, these infrequent human studies were not prospective and randomised, nor did they compare in a homogeneous patient population preserved and preservative free preparations of antiglaucoma drugs. Our crossover randomised study was designed with healthy volunteers to look for diVerences of tolerance between two preparations of carteolol, with and without preservative, in short term use. We confirmed good tolerance for both preparations, which is consistent with the safety of this *Decrease in BUT at 3 hours from baseline was significantly lower in the benzalkonium free group than in the preserved carteolol (p=0.04). †Significantly lowered compared with baseline (p=0.001). drug reported in clinical studies with preserved carteolol. 13 18 19 We also found in this study that the IOP lowering eVect of carteolol was not reduced by suppressing benzalkonium. We observed that the decrease in IOP (around 2.5 mm Hg at peak) was in accordance with previously published studies on carteolol. [18] [19] [20] [21] It has been suggested that benzalkonium chloride, through its toxic eVects on ocular surface epithelia, enhances penetration of the active compound. Controversies thus remain concerning the eVectiveness of unpreserved antiglaucoma drugs. Betaxolol without preservative appeared to be as eYcient as the commercial solution in reducing IOP, 22 and De Jong et al 11 confirmed that unpreserved timolol was both less toxic than, and as eVective on IOP as, the preserved solution.
In the present work, we found a significantly decreased break up time after one drop of and after a 3 day treatment with preserved carteolol compared with the unpreserved preparation which did not modify tear fluid stability significantly. This is probably due to the surfactant property of benzalkonium chloride. However, these results in young healthy volunteers could be much more relevant in older glaucoma patients, who often suVer from various ocular surface disorders and quantitative or qualitative tear deficiency. Inflammatory changes can be found in the conjunctiva of a majority of multitreated glaucoma patients. Whether or not benzalkonium chloride is the main factor responsible for ocular surface toxicity remains to be determined. Only long term well controlled randomised prospective studies comparing preserved with unpreserved blockers, in patients with and without ocular surface diseases, can address this issue. Our study is one of the first attempts, but these results need to be confirmed in large assays in glaucoma patients for a conclusive investigation of the consequences of long term use of preservatives on fragile ocular structures. Studies of preservative eVects may stimulate interest in developing unpreserved solutions for patients with a high risk of toxicity or undergoing filtering surgery.
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